Related Experiment Video
Updated: Jan 17, 2026
09:32
Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
Published on: September 26, 2019
7.6K
Biologics to Treat Atopic Dermatitis: Effectiveness, Safety, and Future Directions
Marjolein S de Bruin-Weller1, Celeste M Boesjes1, Roselie A Achten1
1National Expertise Center for Atopic Dermatitis, Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht, the Netherlands.
Allergy
|September 24, 2025
Summary
Atopic dermatitis (AD) treatments have advanced with targeted biologic therapies like dupilumab, blocking key inflammatory cytokines. This review examines real-world data on these effective and safe options for severe AD management.
Area of Science:
- Dermatology
- Immunology
- Pharmacology
Background:
- Atopic dermatitis (AD) is a prevalent chronic inflammatory skin condition with variable severity.
- Severe AD often necessitates systemic treatments, historically limited by toxicity and efficacy.
- Recent advancements focus on targeted biologic therapies due to improved understanding of AD pathophysiology.
Purpose of the Study:
- To review real-world data on the effectiveness and safety of biologic therapies for atopic dermatitis.
- To provide clinical guidance for the use and side effect management of these novel treatments.
- To briefly discuss emerging therapeutic targets in late-stage clinical trials.
Main Methods:
- Systematic review of real-world evidence on biologic agents for AD.
- Analysis of data on dupilumab, tralokinumab, lebrikizumab, and nemolizumab.
- Inclusion of information on cytokine targets (IL-4, IL-13, IL-31) and their roles.
Main Results:
- Biologic therapies demonstrate effectiveness in controlling severe AD and relieving symptoms.
- These targeted agents offer improved safety profiles compared to traditional immunosuppressants.
- Real-world data support the efficacy and tolerability of approved biologics.
Conclusions:
- Targeted biologic therapies represent a significant advancement in managing moderate-to-severe atopic dermatitis.
- Clinical guidance is essential for optimizing patient outcomes and managing potential adverse events.
- Ongoing research into new therapeutic targets promises further improvements in AD treatment.
Related Concept Videos
01:28Drug Products: Biologics, Biosimilars and Interchangeables
235
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
235
01:29Inflammatory Bowel Disease IV: Pharmacological Management
521
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
521
01:29Microorganisms in Medicine and Therapeutics
982
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
982
01:22Biopharmaceutical Factors Influencing Drug Product Design: Overview
233
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though...
233
01:28Biopharmaceutics and Pharmacokinetics: Overview
3.3K
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the...
3.3K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
492
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
492